ADORA2A and intestinal disorder: In the present study, the inhibition of A2AR by the antagonist ligand SCH58261 blocked the effects of inosine on PPARγ signaling activation and mucosal barrier improvements, suggesting that A2AR may be a novel target for the treatment of intestinal disorders [59].